Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats

American Journal of Hypertension

Volumn 10, Issue 11, 1997, Pages 1257-1262

  Raij, Leopoldo ^a,b   Hayakawa, Hiroshi ^a   Coffee, Karen ^a   Guerra, Janeth ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antioxidants; Doxazosin; Endothelium; Hypercholesterolemia; Nitric oxide; Vasorelaxation

Indexed keywords

ALPHA TOCOPHEROL; DOXAZOSIN; SELENIUM;

ALPHA TOCOPHEROL DEFICIENCY; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID OXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIOXIDANTS; BODY WEIGHT; DOXAZOSIN; ENDOTHELIUM, VASCULAR; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; RATS; SELENIUM; VITAMIN E DEFICIENCY;

EID: 0031279383     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00265-3     Document Type: Article

References (28)

1. 1. Furchgott RF, Zawadski JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;228:373-374.
2. 2. Furchgott RF, Vanhoutte PM: Endothelium-derived relaxing and contracting factors. FASEB J 1989;3:2007-2018.
3. 3. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
4. 4. Myers PR, Minor RL, Guerra R, et al: The vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitroso-cysteine than nitric oxide. Nature 1990;345:161-163.
5. 5. Azuma H, Ishikawa M, Sekizaki S: Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986;88:411-415.
6. 6. Radomski MW, Palmer RMJ, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;ii:1057-1058.
7. 7. Palmer RMJ, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-666.
8. 8. Bredt DS, Snyder SH: Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990;87:682-685.
9. 9. Busse R, Mülsch A, Fleming I, Hecker M: Mechanisms of nitric oxide release from the vascular endothelium. Circulation 1993;87(suppl V):V18-V25.
10. 10. Miller VM, Aarhus LA, Vanhoutte PM: Modulation of endothelium-dependent responses by chronic alterations of blood flow. Am J Physiol 1986;251:H520-H527.
11. 11. Murad FJ: Cyclic guanosine monophosphate as a mediator of vasodilatation. J Clin Invest 1986;78:1-5.
12. 12. Keaney JF, Jr., Vita JA: Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis 1995;38:129-154.
13. 13. Raij L: Hypertension, endothelium, and cardiovascular risk factors. Am J Hypertens 1991;90(suppl 2A):13S-18S.
14. 14. Simon BC, Cunningham LD, Cohen RA: Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest 1990;86:75-79.
15. 15. Tanner FC, Noll G, Boulanger CM, Luscher TF: Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation 1991;83:2012-2020.
16. 16. Chin JH, Azhar S, Hoffman BB: Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992;89:10-18.
17. 17. Kugiyama K, Kerns SA, Morrisett JD, et al: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low density lipoproteins. Nature 1990;344:160-162.
18. 18. O'Hara Y, Peterson TE, Zheng B, et al: Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation. Arterioscler Thromb 1994;14:1007-1013.
19. 19. Gryglewski RJ, Palmer RMJ, Moncada S: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-456.
20. 1-adrenergic antihypertensive agent. Am J Hypertens 1994;7:159-167.
21. 21. Fillios LC, Andrus SB, Mann GV, Stare FJ: Experimental production of gross atherosclerosis in the rat. J Exp Med 1956;104:539-554.
22. 22. Scott RF, Daoud AS, Florentin RA: Animal models in atherosclerosis, in Wissler RF, Geer JC (eds): The Pathogenesis of Atherosclerosis. Williams & Wilkins Co., Baltimore, 1971, pp 120-146.
23. 23. Raij J, Nagy J, Coffee K, DeMaster EG: Hypercholesterolemia promotes endothelial dysfunction in vitamin E-and selenium-deficient rats. Hypertension 1993;22:56-61.
24. 24. Luscher TF, Vanhoutte PM, Raij L: Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension 1987;9(suppl III):193-197.
25. 25. Raij L, Luscher TF, Vanhoutte PM: High potassium diet augments endothelium-dependent relaxations in the Dahl rat. Hypertension 1988;13:562-567.
26. 26. Vatassery GT, Smith WE: Determination of α-tocopherolquinone (vitamin E quinone) in human serum, platelets, and red cell membrane samples. Anal Biochem 1987;177:411-417.
27. 27. Gey KF, Puska P: Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann NY Acad Sci 1989; 570:278-282.
28. 28. Vita JA, Treasure CB, Nabel EG, et al: Coronary vasomotor response to acetylcholine relates to risk factors for coronary heart disease. Circulation 1990;81:491-497.